Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

MRD analysis of the randomized GLOW trial of fixed-duration ibrutinib-venetoclax vs chlorambucil-obinutuzumab in older or comorbid first-line CLL, relating MRD status to PFS. Level 2 (MRD analysis of an RCT; therapy was fixed-duration, not MRD-guided).

J Clin OncolPubMed 37279408